Name (Synonyms) | Correlation | |
---|---|---|
drug636 | Liver injury Wiki | 0.32 |
drug4 | 0.9% Sodium-chloride Wiki | 0.32 |
drug101 | Aviptadil (VIP) Wiki | 0.32 |
drug313 | Convalescent Plasma Transfusion Wiki | 0.32 |
drug164 | Biosensors Wiki | 0.32 |
drug33 | AV-COVID-19 Wiki | 0.32 |
drug483 | Heparin Wiki | 0.32 |
drug458 | Gimsilumab Wiki | 0.32 |
drug1203 | Ultrasound lung imaging as part of FAST+ evaluation Wiki | 0.32 |
drug94 | Atorvastatin Wiki | 0.32 |
drug1336 | mRNA in urine test Wiki | 0.32 |
drug1123 | Tacrolimus Wiki | 0.32 |
drug941 | Random Donor Plasma Wiki | 0.32 |
drug1102 | Supportive Care Wiki | 0.22 |
drug621 | L-ascorbic acid Wiki | 0.22 |
drug108 | Azithromycin Wiki | 0.12 |
drug697 | Methylprednisolone Wiki | 0.11 |
drug850 | Placebo Wiki | 0.08 |
drug505 | Hydroxychloroquine Wiki | 0.07 |
drug865 | Placebo oral tablet Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.40 |
D015428 | Myocardial Reperfusion Injury NIH | 0.32 |
D015427 | Reperfusion Injury NIH | 0.32 |
D055371 | Acute Lung Injury NIH | 0.16 |
D004417 | Dyspnea NIH | 0.14 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.14 |
D058186 | Acute Kidney Injury NIH | 0.13 |
D002318 | Cardiovascular Diseases NIH | 0.08 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D013577 | Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002098 | Respiratory distress HPO | 0.14 |
HP:0001919 | Acute kidney injury HPO | 0.13 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.08 |
There are 10 clinical trials
The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury (AKI) among individuals with COVID-19.
Description: the incidence of Acute Kidney Injury
Measure: Rate of Acute Kidney Injury Time: From date of admission until the date of discharge or death from any cause, up to 60 daysDescription: death from any cause in the hospital
Measure: Rate of Death Time: From date of admission until the date of death from any cause, up to 60 daysDescription: days from admission to discharge or death
Measure: the length of hospital stay Time: From date of admission until the date of discharge or death from any cause, up to 60 daysThe current COVID-19 pandemic is providing healthcare organizations with considerable challenges and opportunities for rapid cycle improvement efforts, in diagnostic and patient management arenas. Healthcare providers are tasked with limiting the use of personal protective equipment while minimizing unnecessary exposures to the virus. Results from real-time PCR tests to detect active COVID-19 infections may not be available in a timely fashion during emergent trauma assessments. Since the start of the COVID-19 pandemic, a rapidly expanding body of literature has identified a pattern of imaged lung abnormalities with CT and ultrasound (US) characteristic of an active viral infection. US evaluation provides a reliable, portable, and reproducible way of evaluating acute patients in a real time setting. During initial trauma evaluations, patients may also receive adjunct imaging modalities like the Focused Assessment with Sonography in Trauma (FAST) exam designed to discover life threatening findings that may require urgent interventions. We therefore propose a study expanding on the current FAST adjunct evaluation in the trauma bay that may include lung parenchyma imaging at the initial assessment to help stratify patients into low or high-risk groups for active COVID-19 infections. We believe the use of point of care US in the initial assessment of the trauma patient may help identify potentially infected individuals and aid ED providers to best directing subsequent laboratory and imaging evaluations for these patients, while further directing the necessary protective measures for additional team members involved in the care of the injured patient.
Description: Will correlate FAST+ pulmonary findings and published CT findings noted in active COVID infection to determine if FAST+ is a suitable diagnostic tool in detecting active COVID infection. Plan to use FAST+ imaging findings to stratify patients into low or high-risk COVID-19 infection groups.
Measure: Correlation of FAST+ pulmonary findings with active COVID infection Time: 12 monthsDescription: Exploratory outcomes will focus on description of additional ancillary findings of the FAST+ examination in those patients who later are determined to be COVID-19 positive compared to those determined to be COVID-19 negative (e.g., patterns of pleural space disease).
Measure: Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients Time: 12 monthsThe primary objective of the study is to evaluate the days until reaching clinical stability after starting randomization in hospitalized patients with elevated inflammatory parameters and severe COVID-19 lung injury.
Description: Assess the days until clinical stability is achieved after initiating randomization in hospitalized patients with elevated inflammatory parameters and severe COVID-19 lung injury. Clinical stability is defined if all the following criteria are met for 48 consecutive hours: Body temperature ≤ 37.0ºC; PaO2 / FiO2> 400 and / or SatO2 / FiO2> 300; Respiratory rate ≤ 24 rpm
Measure: Time to reach clinical stability Time: 28 daysDescription: days
Measure: Time to reach an afebrile state for 48 hours. Time: 56 daysDescription: days
Measure: Time to reach PaO2 / FiO2> 400 and / or SatO2 / FiO2> 300 Time: 56 daysDescription: days
Measure: Time to reach FR ≤ 24 rpm for 48 hours Time: 56 daysDescription: days
Measure: Time to normalization of D-dimer (<250 ug / L) Time: 56 daysDescription: days
Measure: Time until PCR normalization (<5mg / L). Time: 56 daysDescription: days
Measure: Time until normalization of ferritin (<400ug / L) Time: 56 daysDescription: viral load
Measure: Study the impact of immunosuppressive treatment on viral load using quantitative PCR Time: 56 daysDescription: days
Measure: Time until hospital discharge Time: 56 daysDescription: days
Measure: Need for ventilatory support devices Time: 56 daysDescription: days
Measure: Duration that it is necessary to maintain ventilatory support. Time: 56 daysDescription: days
Measure: COVID-19 mortality Time: 56 daysDescription: days
Measure: all-cause mortality Time: 56 daysDescription: cytokines quantification technique by Luminex
Measure: Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission Time: 56 daysDescription: IDIBELL Clinical Research and Clinical Trials Unit will oversee the monitoring and pharmacovigilance
Measure: Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone. Time: 56 daysThis study will test to see if a 72-hour intravenous vitamin C infusion protocol (100 mg/kg every 8 hours) in patients with hypoxemia and suspected COVID-19 will reduce the lung injury caused by the SARS-Cov-2.
Description: Documented days free off mechanical ventilation the first 28 days post enrollment
Measure: Number of ventilator-free days Time: Up to 28 daysDescription: Mortality at 28-days by all causes
Measure: All-cause-mortality Time: Up to 28 daysDescription: Number of days free of acute inflammation (defined as CRP >= 10 mg/L)
Measure: Acute-inflammation-free days Time: Up to 28 daysDescription: Number of days that the participant is free of organ failure in ALL of the following organ systems: Cardiovascular, Respiratory, Neurological, Liver, Bone marrow organ, Renal
Measure: Organ-failure-free days Time: Up to 1 yearStudy KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19.
Description: Mortality at Day 43
Measure: Primary endpoint Time: 43 daysDescription: Subjects who die will be assigned "0" ventilator-free days
Measure: Number of ventilator-free days. Time: Day 43Coronavirus disease was first diagnosed in December 2019, in the city of Wuhan, China. The World Health Organization recently declared coronavirus disease 2019 (COVID-19) as a pandemic. The infection is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a single-stranded RNA virus, which in humans causes mild respiratory symptoms and generally has a good prognosis. However, in a certain group of patients it manifests as severe pneumonia, respiratory distress syndrome, multiple organ dysfunction and death. The factors associated with a worse prognosis are older than 60 years, the presence of diabetes, cardiovascular disease and obesity. According to studies carried out in the Eastern world, the prevalence of liver injury in patients with COVID-19 disease varies between 14% and 53%, being more prevalent in patients with severe symptoms of COVID-19 disease. It is not really known whether the liver involvement of patients with SARS-CoV-2 infection is secondary to the direct effect of the virus on the liver. One of the mechanisms of action of SARS-CoV-2 is through the binding to the angiotensin-converting enzyme receptor, which is present in cholangiocytes, this could explain its excretion in faeces. However, liver injury could be due to the immune response generated in the body by the virus with systemic inflammatory response syndrome and the release of inflammatory cytokines such as IL6, generating direct cytopathic damage to the liver. On the other hand, it could be the product of hepatotoxic drugs administered during hospitalization, such as antibiotics, antivirals or non-steroidal anti-inflammatory drugs. Liver biopsy described microvacuolar steatosis, and a mild portal and lobular inflammatory infiltrate . Therefore, the aim this study is to assess the prevalence of liver complications (liver injury, decompensation of cirrhosis) in patients diagnosed with COVID-19 in Latin America. As secondary objectives, the investigators will describe the clinical characteristics of COVID-19 disease and identify risk factors associated with poor prognosis,
Description: Hospitalized patients with COVD-19 who developed liver injury
Measure: Liver injury in patients with COVID-19 Time: through study completion, an average of 6 monthsDescription: Factors associated with worse outcome
Measure: Prognostic factors associated with death Time: through study completion, an average of 6 monthsDescription: Description of patients hospitalized with COVID-19
Measure: Clinical characteristics of patients who developed liver injury Time: through study completion, an average of 6 monthsBrief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Acute Respiratory Distress Syndrome and the need for mechanical ventilation. Mortality rates as high as 80% have been reported among those who develop ARDS, despite intensive care and mechanical ventilation. Patients with COVID-19 induced non-Acute Lung Injury who have demonstrated reduction in blood oxygenation, dyspnea, and exercise intolerance but do not require endotracheal intubation and mechanical ventilation will be treated with Aviptadil, a synthetic version of Vasoactive Intestinal Polypeptide (VIP) plus Standard of Care vs. placebo + Standard of Care. Patients will be randomized to intravenous Aviptadil will receive inhaled Aviptadil, 100 μg 3x daily vs. placebo 3x daily. The primary outcome will be progression to ARDS over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFα IL-6 and other cytokines.
Description: Progression to ARDS is defined as the need for mechanical ventilation
Measure: Progression to ARDS Time: 28 daysDescription: Blood PO2 as measured by pulse oximetry
Measure: Blood oxygenation Time: 28 daysDescription: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath = very mild shortness of breath = mild shortness of breath = moderate shortness of breath or breathing difficulty = somewhat severe shortness of breath = strong or hard breathing 7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity
Measure: RDP Dsypnea Scale Time: 28 daysDescription: Distance walked in six minutes
Measure: Distance walked in six minutes Time: 28 daysThe authors hypothesize that the SARS-CoV-2 virus can affect the kidneys, causing them to be damaged. The present study aims to explain the mechanisms of kidney injury in patients diagnosed with COVID-19.
Description: estimated glomerular filtration rate (eGFR), ml/min, in groups with mild, moderate and severe COVID-19
Measure: The effect of COVID-19 severity on the severity of renal failure Time: 2 monthsDescription: viral RNA concentration in urine, ME/ml
Measure: The expression of viral RNA in the urine with the severity of renal failure Time: 2 monthsDescription: albumine excretion with urine, g/ml
Measure: The severity of microalbuminuria in patients with COVID-19 of different conditions and renal failure Time: 2 monthsDescription: estimated glomerular filtration rate (eGFR), ml/min
Measure: Assessment of the severity of renal impairment in patients who died from COVID-19 Time: 2 monthsDescription: Duration of viral RNA detection in urine by PCR, weeks
Measure: Estimation of the duration of urinary viral RNA isolation in patients undergoing COVID-19 Time: 2 monthsDescription: expression of ACE-2 by imminohistochemistry at autopsy specimen
Measure: Expression of ACE-2 receptors in the kidneys of patients with renal failure who died from COVID-19 Time: 2 monthsRandomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.
Description: Number of death during hospitalization
Measure: Number of In-Hospital Death Time: During hospitalization, average 2-3 weeksDescription: Length of stay in the hospital
Measure: Length of Stay Time: During hospitalization, average 2-3 weeksDescription: Successful treatment will be defined by two consecutive negative tests for COVID-19
Measure: Number of Successful Treatment Time: During hospitalization, average 2-3 weeks